UPDATE 2-Bristol-Myers cancer ruling hits shares after strong earnings


FILE PHOTO: Logo of global biopharmaceutical company Bristol-Myers Squibb is pictured at the headquarters in Le Passage, near Agen, France, March 29, 2018. REUTERS/Regis Duvignau/File Photo The company said it was notified on Wednesday of the pending negative decision for the use of Opdivo and Yervoy as combination therapy for first-line kidney cancer by the Committee for Medicinal Products for Human Use , part of the European Medicines Agency.



from Biotech News